Moreover, the results of a genome‐wide association study has implicated the triggering receptor expressed on myeloid cells 2 (TREM2) gene, which encodes a microglial cell surface protein, as the second most significant risk factor for late onset AD after APOE ε4 (Guerreiro et al., 2013). This evidence concerns the gene APOE and Alzheimer disease.